Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate “Tripartisan” Medicare Rx Drug Bill To Have 50% Copay, $35 Premium

Executive Summary

The Medicare prescription drug bill under development by a five-member "tripartisan" coalition within the Senate Finance Committee includes a 50% copay and a $35 monthly premium

You may also be interested in...



Rx Cost-Effectiveness Data Requirement Would Raise Prices – AstraZeneca

Requiring pharmaceutical companies to collect cost-effectiveness data would lead to higher Rx pricing, AstraZeneca CEO Tom McKillop said during the company's annual business review Nov. 7

Rx Cost-Effectiveness Data Requirement Would Raise Prices – AstraZeneca

Requiring pharmaceutical companies to collect cost-effectiveness data would lead to higher Rx pricing, AstraZeneca CEO Tom McKillop said during the company's annual business review Nov. 7

Senate Change Puts Hatch, Gregg, Grassley In Line For Key Rx Committees

The transfer of control in the Senate puts Sen. Orrin Hatch (R-Utah) in position to have greater influence in guiding generic drug reform legislation

Related Content

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel